Best helicobacter pylori eradication strategy in the era of antibiotic resistance
- Authors
- Kim, Su Young; Chung, Jun-Won
- Issue Date
- Aug-2020
- Publisher
- MDPI
- Keywords
- Antibiotic resistance; Eradication; Helicobacter pylori
- Citation
- ANTIBIOTICS-BASEL, v.9, no.8, pp.1 - 16
- Journal Title
- ANTIBIOTICS-BASEL
- Volume
- 9
- Number
- 8
- Start Page
- 1
- End Page
- 16
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78193
- DOI
- 10.3390/antibiotics9080436
- ISSN
- 2079-6382
- Abstract
- Antibiotic resistance is the major reason for Helicobacter pylori treatment failure, and the increasing frequency of antibiotic resistance is a challenge for clinicians. Resistance to clarithromycin and metronidazole is a particular problem. The standard triple therapy (proton pump inhibitor, amoxicillin, and clarithromycin) is no longer appropriate as the first-line treatment in most areas. Recent guidelines for the treatment of H. pylori infection recommend a quadruple regimen (bismuth or non-bismuth) as the first-line therapy. This treatment strategy is effective for areas with high resistance to clarithromycin or metronidazole, but the resistance rate inevitably increases as a result of prolonged therapy with multiple antibiotics. Novel potassium-competitive acid blocker-based therapy may be effective, but the data are limited. Tailored therapy based on antimicrobial susceptibility test results is ideal. This review discussed the current important regimens for H. pylori treatment and the optimum H. pylori eradication strategy. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78193)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.